Review

You have free access to this content

The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia

  1. Carolyn Owen1,*,
  2. Jude Fitzgibbon2,
  3. Peter Paschka3

Article first published online: 9 DEC 2009

DOI: 10.1002/hon.931

Issue

Hematological Oncology

Hematological Oncology

Volume 28, Issue 1, pages 13–19, March 2010

Additional Information

How to Cite

Owen, C., Fitzgibbon, J. and Paschka, P. (2010), The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematol. Oncol., 28: 13–19. doi: 10.1002/hon.931

Author Information

  1. 1

    Division of Hematology and Hematological Malignancies, University of Calgary, Calgary, Canada

  2. 2

    Department of Medical Oncology, Barts and the London School of Medicine, London, UK

  3. 3

    Department of Hematology, Oncology, Rheumatology and Infectious Diseases, University Hospital of Ulm, Ulm, Germany

*Division of Hematology & Hematological Malignancies, 601A South Tower, Foothills Medical Centre, 1403-29th Street NW, Calgary, Alberta, T2N 2T9, Canada.

Publication History

  1. Issue published online: 15 MAR 2010
  2. Article first published online: 9 DEC 2009
  3. Manuscript Accepted: 11 SEP 2009
  4. Manuscript Received: 7 SEP 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (116K)

References

  • 1
    Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.
  • 2
    Byrd JC, Mrozek K, Dodge RK, Carroll, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336.
  • 3
    Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083.
  • 4
    Mrozek K, Bloomfield CD. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. J Natl Cancer Inst Monogr 2008; 39: 52–57.
  • 5
    Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909–1918.
  • 6
    Schlenk RF, Dohner K. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol 2009; 16: 98–104.
  • 7
    Vardiman JW, Thiele J, Arber DA, Brunning, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.
  • 8
    Nakao M, Yokota S, Iwai T, Kaneko, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918.
  • 9
    Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266.
  • 10
    Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27: 263–270.
  • 11
    Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 2004; 64: 8816–8820.
  • 12
    Caligiuri MA, Briesewitz R, Yu J, et al. Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 2007; 110: 1022–1024.
  • 13
    Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23: 1343–1345.
  • 14
    Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788–800.
    Direct Link:
  • 15
    van Haaften G, Dalgliesh GL, Davies H, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41: 521–523.
  • 16
    Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009.
  • 17
    Scott RH, Stiller CA, Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 2006; 43: 705–715.
  • 18
    Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 2005; 5: 699–712.
  • 19
    Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079.
  • 20
    Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21: 868–876.
  • 21
    Ito K, Oji Y, Tatsumi N, et al. Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 2006; 25: 4217–4229.
  • 22
    Reddy JC, Morris JC, Wang J, English, et al. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem 1995; 270: 10878–10884.
  • 23
    Morrison AA, Venables JP, Dellaire G, Ladomery MR. The Wilms tumour suppressor protein WT1 (+KTS isoform) binds alpha-actinin 1 mRNA via its zinc-finger domain. Biochem Cell Biol 2006; 84: 789–798.
  • 24
    Gu W, Hu S, Chen Z, et al. High expression of WT1 gene in acute myeloid leukemias with more predominant WT1+17AA isoforms at relapse. Leuk Res 2009 May 2 [Epub].
  • 25
    Hossain A, Nixon M, Kuo MT, Saunders GF. N-terminally truncated WT1 protein with oncogenic properties overexpressed in leukemia. J Biol Chem 2006; 281: 28122–28130.
  • 26
    Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007; 9: 1–17.
  • 27
    Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405–409.
  • 28
    Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060–1067.
  • 29
    Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 2004; 125: 590–600.
    Direct Link:
  • 30
    Brieger J, Weidmann E, Fenchel K, Mitrou PS, Hoelzer D, Bergmann L. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 1994; 8: 2138–2143.
  • 31
    Schmid D, Heinze G, Linnerth B, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997; 11: 639–643.
  • 32
    Lapillonne H, Renneville A, Auvrignon A, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006; 24: 1507–1515.
  • 33
    Weisser M, Kern W, Rauhut S, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005; 19: 1416–1423.
  • 34
    Barragan E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004; 89: 926–933.
  • 35
    Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008; 93: 921–924.
  • 36
    Cilloni D, Gottardi E, De Micheli D, Serra, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16: 2115–2121.
  • 37
    Ommen HB, Nyvold CG, Braendstrup K, et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 2008; 141: 782–791.
    Direct Link:
  • 38
    Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009; 82: 61–68.
    Direct Link:
  • 39
    Hamalainen MM, Kairisto V, Juvonen V, et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol 2008; 80: 201–207.
    Direct Link:
  • 40
    Rodrigues PC, Oliveira SN, Viana MB, et al. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia. Pediatr Blood Cancer 2007; 49: 133–138.
    Direct Link:
  • 41
    Yanada M, Terakura S, Yokozawa T, et al. Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia. Leuk Lymphoma 2004; 45: 1803–1808.
  • 42
    Noronha SA, Farrar JE, Alonzo TA, et al. WT1 expression at diagnosis does not predict survival in pediatric aml: A report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 53: 1136–1139.
    Direct Link:
  • 43
    Gaiger A, Linnerth B, Mann G, et al. Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol. Eur J Haematol 1999; 63: 86–93.
  • 44
    Busse A, Gokbuget N, Siehl JM, et al. Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Ann Hematol 2009; 88: 1199–1205.
  • 45
    Boublikova L, Kalinova M, Ryan J, et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006; 20: 254–263.
  • 46
    Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in T-ALL. Blood 2009; 114: 1038–1045.
  • 47
    Algar EM. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 1996; 12: 1005–1014.
  • 48
    Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885–13890.
  • 49
    Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236–242.
  • 50
    Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009; 113: 6541–6548.
  • 51
    Pritchard-Jones K, Renshaw J, King-Underwood L. The Wilms tumour (WT1) gene is mutated in a secondary leukaemia in a WAGR patient. Hum Mol Genet 1994; 3: 1633–1637.
  • 52
    King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998; 91: 2961–2968.
  • 53
    Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005; 65: 375–378.
  • 54
    Fitzgibbon J, Smith LL, Raghavan M, et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005; 65: 9152–9154.
  • 55
    Summers K, Stevens J, Kakkas I, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 2007; 21: 550–551 author reply 552.
  • 56
    King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms' tumor gene WT1 in leukemias. Blood 1996; 87: 2171–2179.
  • 57
    Virappane P, Gale R, Hills R, Kakkas, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26: 5429– 5435.
  • 58
    Paschka P, Marcucci G, Ruppert AS, Whitman, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008; 26: 4595–4602.
  • 59
    Gaidzik VI, Schlenk RF, Moschny S, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009; 113: 4505–4511.
  • 60
    Renneville A, Boissel N, Zurawski V, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer 2009; 115: 3719–3727.
    Direct Link:
  • 61
    Thiede C, Illmer T, Soucek S, Schaich M, Ehninger G. Mutations in the WT1 transcription factor are associated with inferior overall survival - an analysis in 368 AML patients with normal karyotype under 60 years treated in the AML96 protocol of the DSIL. Haematologica 2008; 93: 62 [abstract].
  • 62
    Spinelli O, Tosi M, Guerini V, et al. Prognostic signifiance of molecular markers in normal karyotype-AML: a single centre experience. Haematologica 2008; 91: 206 [abstract].
  • 63
    Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 2009; 113: 5951–5960.
  • 64
    Abbas S, Erpelinck C, Goudswaard C, Lowenberg B, Valk P. Mutant Wilms' Tumor 1 (WT1) mRNA with premature termination codons is sensitive to nonsense-mediated RNA decay in Acute Myeloid Leukemia (AML). Blood 2008; 112: 2538 [abstract].
  • 65
    Chou WC, Chen CY, Hou HA, et al. Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients. Leukemia 2009; 23: 1303–1310.
  • 66
    Ruf RG, Schultheiss M, Lichtenberger A, et al. Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int 2004; 66: 564–570.
  • 67
    Borel F, Barilla KC, Hamilton TB, Iskandar M, Romaniuk PJ. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1. Biochemistry 1996; 35: 12070–12076.
  • 68
    Hasle H, Arico M, Basso G, Biondi, et al. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS). Leukemia 1999; 13: 376–385.
  • 69
    Patek CE, Little MH, Fleming S, et al. A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome. Proc Natl Acad Sci USA 1999; 96: 2931–2936.
  • 70
    Gao F, Maiti S, Sun G, et al. The Wt1+/R394W mouse displays glomerulosclerosis and early-onset renal failure characteristic of human Denys-Drash syndrome. Mol Cell Biol 2004; 24: 9899–9910.
  • 71
    Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776–2784.
  • 72
    Miyagawa K, Hayashi Y, Fukuda T, Mitani K, Hirai H, Kamiya. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. Gene Chromosome Canc 1999; 25: 176–183.
    Direct Link:
  • 73
    Willasch AM, Gruhn B, Coliva T, et al. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia 2009; 23: 1472–1479.
  • 74
    Pollard J, Zeng R, Ho P, et al. Prevalence and prognostic implications of WT1 mutations in pediatric AML: a report from the children's Oncology Group. Blood 2008; 112: 143 [abstract].
  • 75
    Nyvold CG, Stentoft J, Braendstrup K, et al. Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: biological and clinical implications. Leukemia 2006; 20: 2051–2054.
Get PDF (116K)